Early Coronary Angiography in Advanced Chronic Kidney Disease With Acute Coronary Syndrome (CAG in CKD-ACS)

March 11, 2026 updated by: Thana Thongsricome, MD, Chulalongkorn University

Early Coronary Angiography Associates With Survival Benefit and Longer Time to Initiation of Renal Replacement Therapy in Patients With Advanced Chronic Kidney Disease and Acute Coronary Syndrome: A Survival Analysis

This is the retrospective study regarding the association of invasive coronary angiography and time to renal replacement therapy initiation and mortality in patients with chronic kidney disease stage 4-5 who develop acute coronary syndrome.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Electronic medical records of adult patients admitted with ACS, by the recorded diagnosis code, between 1 January 2017 and 31 December 2021 at King Chulalongkorn Memorial Hospital, Thailand, were retrospectively reviewed. Eligible patients should have concurrent advanced stage CKD, defined as an eGFR less than 30 mL/min/1.73 m² calculated by the 2021 CKD-EPI creatinine equation.

Study Type

Observational

Enrollment (Actual)

139

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with pre-dialysis CKD stage 4-5 with acute coronary syndrome

Description

Inclusion Criteria:

  • Advanced stage CKD, defined as an eGFR less than 30 mL/min/1.73 m²
  • Diagnosis with ACS, by the recorded diagnosis code, between 1 January 2017 and 31 December 2021 at King Chulalongkorn Memorial Hospital

Exclusion Criteria:

  • Received maintenance dialysis or kidney transplantation before admission
  • Cardiogenic shock or cardiac arrest
  • Prior PCI or CABG within 12 months
  • Recently diagnosed with ACS within 2 months
  • Had a limited life expectancy due to non-cardiovascular disease
  • Pregnant.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Early coronary angiography
Recieve coronary angiography within 24 hours of admission
Procedure: coronary angiography
Standard coronary angiography
Other Names:
  • medication
Delayed coronary angiography
Recieve coronary angiography later than 24 hours of admission
Procedure: coronary angiography
Standard coronary angiography
Other Names:
  • medication
Conservative management
Medical management without coronary angiography

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Renal replacement therapy initiation
Time Frame: Until 31 December 2021
Renal replacement therapy initiation
Until 31 December 2021

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
All-cause mortality
Time Frame: Until 31 Dec 2021
All-cause mortality
Until 31 Dec 2021

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chulalongkorn University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2017

Primary Completion (Actual)

December 31, 2021

Study Completion (Actual)

December 31, 2021

Study Registration Dates

First Submitted

March 11, 2026

First Submitted That Met QC Criteria

March 11, 2026

First Posted (Actual)

March 16, 2026

Study Record Updates

Last Update Posted (Actual)

March 16, 2026

Last Update Submitted That Met QC Criteria

March 11, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 046367
  • 0463/67 (Other Identifier: Institutional review board of the Faculty of Medicine, Chulalongkorn University)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

All data generated or analyzed during this study are included in this article.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on CKD

Clinical Trials on coronary angiography

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe